Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of topiroxostat on urinary albumin
excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia
with or without gout. Participants are randomized to placebo (n=20) or topiroxostat (n=40)
for 28 weeks. The investigational drugs for this study are supplied by FUJI YAKUHIN CO., LTD.